tbuckley/cabot-search huggingface dataset:
AB0929 Neutrophil/lymphocyte Ratio (NLR), Platelet/lymphocyte Ratio (PLR) Were Useful Markers in Assessment of Inflammatory Response in Aosd Patients
Authors: W.S. Lee, Y.-J. Choi, M.-J. Hong, C.-H. Lee, M.S. Lee, S.-I. Lee, Y.-H. Cheon, W.-H. Yoo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Both neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR) are reported to be increased in various inflammatory diseases, but there clinical significance in adult onset still disease (AOSD) remains unclear. <h3>Objectives</h3> The aim of the present study was to evaluate NLR and PLR as a inflammatory marker in AOSD. <h3>Methods</h3> The medical records of 23 AOSD patients and age, sex-matched 25 healthy individuals were retrospectively reviewed. NLR, PLR between AOSD patients and healthy controls were compared, and correlation between these indexes and clinical characteristics were analyzed. Exclusion criteria included active infection and/or the presence of any hematological, cardiovascular or metabolic disorder. <h3>Results</h3> The NLR and PLR were found to be significantly higher in AOSD patients when compared to the healthy control (NLR: 10.67± 6.73 vs 2.05±1.07, p&lt;0.001, PLR: 255.78±107.22 vs 128.10 ±42.60, p&lt;0.001). The NLR and PLR were decreased significantly after treatment (4.67±3.22, 196.84±78.54). NLR was positively correlated with erythrocyte sedimentation rate (ESR)(r=0.612, p&lt;0.001), C-reaction protein (CRP)(r=0.597, p&lt;0.001) and ferritin (r=0.552, p&lt;0.001). PLR was positively correlated with ESR (r=0.648, p&lt;0.001), CRP (r=0.536, p&lt;0.001) except ferritin (r=0.33, p=0.025). <h3>Conclusions</h3> NLR, PLR, together with other serum inflammatory markers, were proving as significant clinical tools which could be used as biomarkers for inflammatory response of disease activity in AOSD patients. <h3>Disclosure of Interest</h3> None declared
Potentially Preventable Deaths Among the Five Leading Causes of Death — United States, 2010 and 2014
Authors: Macarena C. García, Brigham Bastian, Lauren M. Rossen, Robert Anderson, Arialdi Miniño, Paula W. Yoon, Mark Faul, Greta Massetti, Cheryll C. Thomas, Yuling Hong, Michael F. Iademarco
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Death rates by specific causes vary across the 50 states and the District of Columbia.* Information on differences in rates for the leading causes of death among states might help state health officials determine prevention goals, priorities, and strategies. CDC analyzed National Vital Statistics System data to provide national and state-specific estimates of potentially preventable deaths among the five leading causes of death in 2014 and compared these estimates with estimates previously published for 2010. Compared with 2010, the estimated number of potentially preventable deaths changed (supplemental material at https://stacks.cdc.gov/view/cdc/42472); cancer deaths decreased 25% (from 84,443 to 63,209), stroke deaths decreased 11% (from 16,973 to 15,175), heart disease deaths decreased 4% (from 91,757 to 87,950), chronic lower respiratory disease (CLRD) (e.g., asthma, bronchitis, and emphysema) deaths increased 1% (from 28,831 to 29,232), and deaths from unintentional injuries increased 23% (from 36,836 to 45,331). A better understanding of progress made in reducing potentially preventable deaths in the United States might inform state and regional efforts targeting the prevention of premature deaths from the five leading causes in the United States.
Number of GP consultations rises by 10% in two years, analysis finds
Authors: Gareth Iacobucci
Journal: BMJ (2016)

General practices in England saw an increase of almost 10% in the number of consultations over the past two years, a new analysis has found.

The data from 202 general practices (around 2.5% of all practices in England) was collected by health think tank the King’s Fund, which incorporated an analysis of demand and activity in general practice into its quarterly monitoring report for the first time.

The latest report, covering July to September 2016, found that rises in demand for services across the board were causing the NHS to head into winter with its finances under pressure and performance against several key indicators at its worst for more than a …
Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.
Authors: Chad P. Soupir, Jo-Anne Vergilio, Paola Dal Cin, Alona Muzikansky, Hagop M. Kantarjian, Dan Jones, Robert P. Hasserjian
Journal: Blood (2005)
Expression of Lipoprotein Lipase In Chronic Lymphocytic Leukemia Cells: Is There a Biological Function?
Authors: Edit anna Porpaczy, Stefanie Tauber, Martin Bilban, Gerhard Kostner, Michaela Gruber, Trang Le, Karin Fleiss, Cathrine Skrabs, Christine Einberger, Medhat Shehata, Ulrich Jaeger, Katrina Vanura
Journal: Blood (2010)
APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death
Authors: Yulong Fu, Jun-yi Zhu, Adam Richman, Yi Zhang, Xuefang Xie, Jharna R. Das, Jinliang Li, Patricio E. Ray, Zhe Han
Journal: Journal of the American Society of Nephrology (2016)

People of African ancestry carrying certain APOL1 mutant alleles are at elevated risk of developing renal diseases. However, the mechanisms underlying APOL1-associated renal diseases are unknown. Because the APOL1 gene is unique to humans and some primates, new animal models are needed to understand the function of APOL1 in vivo We generated transgenic Drosophila fly lines expressing the human APOL1 wild type allele (G0) or the predominant APOL1 risk allele (G1) in different tissues. Ubiquitous expression of APOL1 G0 or G1 in Drosophila induced lethal phenotypes, and G1 was more toxic than was G0. Selective expression of the APOL1 G0 or G1 transgene in nephrocytes, fly cells homologous to mammalian podocytes, induced increased endocytic activity and accumulation of hemolymph proteins, dextran particles, and silver nitrate. As transgenic flies with either allele aged, nephrocyte function declined, cell size increased, and nephrocytes died prematurely. Compared with G0-expressing cells, however, G1-expressing cells showed more dramatic phenotypes, resembling those observed in cultured mammalian podocytes overexpressing APOL1-G1. Expressing the G0 or G1 APOL1 transgene in nephrocytes also impaired the acidification of organelles. We conclude that expression of an APOL1 transgene initially enhances nephrocyte function, causing hypertrophy and subsequent cell death. This new Drosophila model uncovers a novel mechanism by which upregulated expression of APOL1-G1 could precipitate renal disease in humans. Furthermore, this model may facilitate the identification of APOL1-interacting molecules that could serve as new drug targets to treat APOL1-associated renal diseases.
Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)
Authors: Alessandro M. Vannucchi, Francesco Passamonti, Haifa Kathrin Al-Ali, Giovanni Barosi, Claire N Harrison, Andres Sirulnik, Viktoriya Stalbovskaya, Matthew Squires, Timothy Burn, Laurent Knoops, Francisco Cervantes, Tiziano Barbui, Heinz Gisslinger, Jean-Jacques Kiladjian
Journal: Blood (2012)
Online tool predicts chances of conceiving with IVF
Authors: Ingrid Torjesen
Journal: BMJ (2016)

An online calculator that predicts a couple’s individualised chances of conceiving, after a single cycle of in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment and over a course of cycles, has been created by researchers using data from the Human Fertilisation and Embryology Authority register, The BMJ reports.1

The researchers included data on 113 873 women who underwent 184 269 complete IVF or ICSI cycles using their own eggs and their partner’s sperm from 1999 to 2008. Of these women, 33 154 (29.1%) had a live birth …
Identification of Blut, a Novel Long-Noncoding RNA Differentially Expressed in Burkitt Lymphoma
Authors: Jessica I Hoell, Kunal Das Mahapatra, Kebria Hezaveh, Andreas Kloetgen, Stephan Bernhart, Steve Hoffmann, Peter Stadler, Dido Lenze, Andrea Haake, Julia Richter, Lorenz H. Truemper, Birgit Burkhardt, Wolfram Klapper, Peter Moeller, Philip Rosenstiel, Chris Lawerenz, Roland Eils, Reiner Siebert, Michael Hummel, Arndt Borkhardt
Journal: Blood (2015)
Novel Roles for the Homeobox Gene, HoxA1, and Its Truncated Form, HoxA1-T, in the Regulation of Hematopoietic Stem Cell Self-Renewal.
Authors: Stewart A. Fabb, Gemma Haines, Seb Dworkin, Paul J. Simmons, Lorraine J. Gudas, Louise E. Purton
Journal: Blood (2004)
THU0531 NOD2/CARD15 Gene Mutations in Patients with Gouty Arthritis
Authors: A. Karaarslan, S. Kobak, A. Berdeli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gouty arthritis is a chronic erosive autoinflammatory disease. NOD2/CARD15 molecule has been shown to play important roles in the etiopathogenesis of many inflammatory diseases, resulting in predisposition to the diseases. NOD2/CARD15 is a cytoplasmic molecule which plays a role in controlling apoptosis as well as inflammatory processes by recognizing some microbial components. <h3>Objectives</h3> The aim of this study was to identify the frequency of NOD2/CARD15 gene mutation in gouty arthritis patients and determine its possible correlation with disease phenotype. <h3>Methods</h3> The study included 93 patients with gouty arthritis and 51 healthy controls matched for age, gender and ethnicity. NOD2/CARD15 gene mutations (R702W and G908R, 3020insC) were studied by PCR method. <h3>Results</h3> Of the 93 patients included in the study, 72 were male and 21 were female. The mean patient age was 54.2±14.2 years, mean duration of the disease was 3.1 ± 2.9 years. In the clinical and laboratory evaluations of gouty arthritis patients; first MTP joint involvement was detected in 72 (77.4%), ankle arthritis in 43 (46.2%), knee arthritis in 20 (21.5%), finger joint involvement in 18 (19.5%) patients, increased serum levels of uric acid in 76 (81.7%) and CRP in 42 (45.2%) patients, and elevated ESR in 45 (48.4%) patients. Totally 4 (9%) heterozygous mutations were detected in the NOD2/CARD15 G908R and NOD2/CARD15 R702W genes, while no mutation was detected in the NOD2/CARD15 C3020ins gene. When compared with the control group, statistically significant difference was not detected for each of three regions (908,702,3020ins) (p=0.452, p=0.583 and p=0.350, respectively). In the patient group, statistically significant correlations were not detected in clinical and laboratory findings (first MTP arthritis, ankle arthritis, increased serum uric acid, ESR and CRP values) of the patients with and without mutations for each of the three regions (p&gt;0.05) <h3>Conclusions</h3> Similar frequency of NOD2/CARD15 gene mutations was detected in patients with gouty arthritis in comparison to healthy control group. Again, no correlation was observed between clinical as well as laboratory findings and NOD2/CARD15 gene mutation. Prospective studies with large series of patients are needed to be carried out on this topic. <h3>Disclosure of Interest</h3> None declared
History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.
Authors: M. Domenica Cappellini, Mohsen Saleh Elalfy, Amal El-Beshlawy, Antonis Kattamis, Lee Lee Chan, ChunFu Li, Kai-Hsin Lin, Giovanni Quarta, Pranee Sutcharitchan, Ali Taher, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter
Journal: Blood (2009)
SAT0176 IL-6 Blockade with Tocilizumab Does Not Suppress CD4+T Cell Activation at 48 Weeks of The Treatment
Authors: M. Murakami, T. Kuritani, N. Nishimoto
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a common immflamatory autoimmune disease characterized by persistent synovitis and progressive destruction of cartilage and bone in multiple joints. The proportion of CD25+CD4+ T cells is increased in anti-citrullinated protein antibodies (ACPA) positive RA patients compared with ACPA negative RA patients. Abatacept (ABA), a biologic blocking T cell co-stimulation, decreased the proportion of CD25+CD4+ T cells and interleukin (IL)-6 levels in ACPA positive RA patients. It has been reported that CD25 expressions are increased by IL-6. Tocilizmab (TCZ) is a humanized anti-human IL-6 receptor antibody that has been developed to inhibit the IL-6 signal as a therapeutic agent. <h3>Objectives</h3> We aimed to investigate whether IL-6 blockade with TCZ decreases the proportion of CD25+CD4+ T cells. <h3>Methods</h3> Peripheral blood mononucleated cells (PBMCs) were obtained from 13 ACPA (+) RA patients at baseline, 24 and 48 weeks of TCZ treatment (male:female ratio = 0.077). Surface phenotypes and activation markers of T cells were analyzed with flow cytometory. <h3>Results</h3> DAS28-ESR and SDAI were significantly reduced at 24 and 48 weeks compared with those at baseline (DAS28-ESR: 4.87±1.25 at baseline; 1.99±1.13 at 24 weeks, <i>p</i>&lt;0.0001; 1.61±0.70 at 48 weeks <i>p</i>&lt;0.0001; SDAI: 20.75±9.56 at baseline; 6.30±7.0 at 24 weeks,<i>p</i>=0.0008; 3.20±2.86 at 48 weeks, <i>p</i>&lt;0.0001). The serum levels of matrix metalloproteinase (MMP)-3 were significantly decreased at 48 weeks (250.5±311.0 ng/mL at baseline; 85.1±81.8 ng/mL at 24 weeks, <i>p</i>=0.07; 54.9±27.2 ng/mL at 48 weeks, <i>p</i>=0.04). The proportion of CD4+ cells was significantly increased at 24 and 48 weeks compared with those at baseline (29.7±18.2% at baseline; 37.3±12.9% at 24 weeks, <i>p</i>=0.0094; 37.7±14.1% at 48 weeks, <i>p</i>=0.025). The proportions of CD25+CD4+ cells in CD4+ cells were not significantly different (5.7±4.2% at baseline; 6.1±3.4% at 24 weeks, <i>p</i>=0.795; 7.1±2.1% at 48 weeks, <i>p=0.247</i>). Also, the proportions of regulatory T (Treg) cells (FoxP3+CD25+CD4+ in CD4+ cells) were not significantly different (0.68±0.67% at baseline; 0.58±0.52% at 24 weeks <i>p=0.752</i>; 0.61±0.53% at 48 weeks, <i>p</i>=0.794). <h3>Conclusions</h3> IL-6 blockade has therapeutic effects on RA patients. However, the blockade does not change proportions of CD4+CD25+ in CD4+ T cells as well as those of Treg cells. Some other mechanisms, besides a decrease in CD4+ activation or an increase in Treg cell proportion, contribute the therapeutic effect of IL-6 blockade. <h3>Disclosure of Interest</h3> M. Murakami Grant/research support from: Chugai Pharmaceutical Co., Ltd., T. Kuritani: None declared, N. Nishimoto Grant/research support from: Chugai Pharmaceutical Co., Ltd., Consultant for: Chugai Pharmaceutical Co., Ltd.
Effects of a Novel, Selective Jak2 Inhibitor, AZ60, on STAT5 Signaling and Cellular Growth in Jak2 V617F Cell Lines.
Authors: Joseph M. Gozgit, Geraldine A. Bebernitz, Pankaj Patil, Minwei Ye, Jiaquan Wu, Stephanos Ioannidis, Audrey Davies, Tao Wang, Dennis Huszar, Michael Zinda
Journal: Blood (2007)
HCP-23PROSPECTIVE ASSESSMENT OF CAREGIVER PERCEPTIONS OF END-OF-LIFE CARE IN PATIENTS WITH HIGH GRADE GLIOMA
Authors: Tobias Walbert, Beverly Stallings, Joel Phillips
Journal: Neuro-Oncology (2015)

BACKGROUND: Little is known about the quality of life experienced by patients and caregivers in the end-of-life (EoL) stage of patients with high grade glioma (HGG). The goal of this study is to understand caregiver perceptions of EoL  of HGG patients in the final 30 days. METHODS: A prospective observational study for patients with HGG and their caregivers was performed. Caregivers were called every 2 weeks during EoL phase and one month after death to participate in the Toolkit After-Death Bereaved Family Member Interview, part of the Toolkit of Instruments to Measure End-of-Life Care (TIME survey). RESULTS: 25 out of 30 caregivers completed the TIME interview. All patients were followed by hospice at time of death. Twenty-one patients (84%) died at home, 2 (8%) at an inpatient hospice and 2(8%) at a  facility. Thirteen patients (52%) had a durable power of attorney but only 2(8%) had a living will. Twenty-one patients (84%) lost consciousness prior to death at a median of 4 days (range 1-7). Overall  from hospice was well perceived well and measured with 5 questions, using a Likert scale (0-10, 10 the best): communication (8.6±1.44), respected wishes (9.4±1.12), symptoms controlled (8.8±1.63), died with dignity (9.6±1.08), providing emotional support (8.2±1.61), best  possible (8.7±1.22). Based on Time survey domain scores, caregivers felt that care coordination and informing and decision making were handled well while advanced  planning, focus on individual and  to family could be slightly improved. CONCLUSIONS: Caregivers were overall satisfied with the EoL  received by patients. Only about half of all patients had a power of attorney in place and 8% had documented their EoL wishes. Earlier palliative  interventions might help to better direct end of life wishes and to improve attention to caregiver needs.
Celiac Disease: Association with Iron Deficiency in Caucasians but Not in Non-Caucasians.
Authors: Joseph A. Murray, Stela McLachlan, Paul C. Adams, John H. Eckfeldt, Chad P. Garner, Chris D. Vulpe, Victor R. Gordeuk, Tricia L. Brantner, Catherine Leiendecker-Foster, Anthony A. Killeen, Ronald T. Acton, Lisa F. Barcellos, Kenneth B. Beckman, Gordon D. McLaren, Christine E. McLaren
Journal: Blood (2012)
Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer
Authors: Louise Carter, Dominic G Rothwell, Barbara Mesquita, Christopher Smowton, Hui Sun Leong, Fabiola Fernandez-Gutierrez, Yaoyong Li, Deborah J Burt, Jenny Antonello, Christopher J Morrow, Cassandra L Hodgkinson, Karen Morris, Lynsey Priest, Mathew Carter, Crispin Miller, Andrew Hughes, Fiona Blackhall, Caroline Dive, Ged Brady
Journal: Nature Medicine (2016)
THU0081 Role of The Soluble Form of Dipeptydil Peptidase-4(DPP4) in The Insulin Resistance of Patients with Rheumatoid Arthritis
Authors: B. Tejera Segura, A. de Vera González, R. Lopez Mejías, B. Ubilla, F. Genre, J. Olmos, J. Hernández, J. Llorca, M. González-Gay, I. Ferraz-Amaro
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Dipeptidyl peptidase 4 (DPP-4) is an enzyme which plays a fundamental role on glucose homeostasis through degradation of the incretine hormones glucagon like peptide 1 and gastric inhibitory polypeptide. <h3>Objectives</h3> To analyze if DPP-4 levels differ between Rheumatoid arthritis (RA) patients and healthy controls, as well as to investigate if they correlate with the insulin resistance (IR) that RA patients express. <h3>Methods</h3> 406 subjects, 178 patients with RA and 228 controls adjusted by age and sex, were selected. We determined in both groups glucose, insulin and C peptide levels, <i>Homeostatic Model Assessment</i> (HOMA2) index for insulin and C peptide, and blood levels of the soluble form of DPP-4. We studied with multivariant analysis adjusted for the intake of steroids and other classic factors associated with IR, the differences between patients and controls as well as the correlation of DPP-4 with the activity of the disease and with IR in both groups. <h3>Results</h3> Patients had higher levels of insulin (16±26 vs 10±7 microU/mL, p=0,001) and C peptide (1,15±1,02 vs 0,50±0,26 nmol/L, p&lt;0,001) compared to controls. Equivalently, insulin resistance index HOMA-IR (1,81±1,82 vs 1,35±0,93, p=0,002) and HOMA2-IR-peptide C (2,59±2,45 vs 1,10±0,55 nmol/L, p&lt;0,001) were higher in patients with RA. DPP-4 levels were lower in patients with RA than controls (beta coef. -162 [-259–65] ng/ml, p=0.001), after adjustment for age, sex, body mass index and classic factors for IR. Patients with high or moderate activity (633±270 vs 844±757 ng/ml, p=0.06) and low activity (761±340 vs 844±756 ng/ml, p=0.40) had a lower expression of DPP-4 levels compared to those patients in remission, although this difference did not reach statistical significance. <h3>Conclusions</h3> Patients with RA express lower levels of DPP-4. This decrease could be explained by the activity of the disease and could play a role in the development of insulin resistance that RA patients express. <h3>Disclosure of Interest</h3> None declared
Minimal Residual Disease by Flow Cytometry in Children with Acute Lymphoblastic Leukemia. Single-Center Experience
Authors: Marcela Eugenia Soria, Marcela Ema Gutierrez, Maria Isabel Gaillard, Maria Cores, Gimena Gil, Lorena Elizabeth Moran, Maria Fernanda Rivas Pereira, Silvina Prada, Guillermo Drelichman, Leonardo Feldman, Luis Alberto Aversa
Journal: Blood (2011)
Exploring the Expression Profile of Long Non-Coding RNA (lncRNA) in Different Acute Myeloid Leukemia (AML) Subtypes: t(8;16)(p11;p13)/MYST3-Crebbp AML Harbors a Distinctive Lncrna Signature
Authors: Marina Diaz-Beya, Alfons Navarro, Anna Cordeiro, Marta Pratcorona, Joan Castellano, Miguel Angel Torrente, Meritxell Nomdedeu, Ruth Risueño, Maria Rozman, Mariano Monzo, Jordi Esteve
Journal: Blood (2015)
Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients
Authors: Robin R. Klebig, Stephen M. Ansell, Joseph P. Colgan, Dennis A. Gastineau, Thomas M. Habermann, Patrick B. Johnston, Svetomir N. Markovic, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Kay M. Ristow, Carrie A. Thompson, Jessica N. Towns, Thomas E. Witzig, David J. Inwards
Journal: Blood (2011)
Third Autotransplant for the Management of 98 Patients among 1358 Who Had Received Prior Tandem Autotransplants: Benefit Apparent When 2nd to 3rd Transplant Interval Exceeds 3 Years.
Authors: Choon Kee Lee, Bart Barlogie, Athanasios Fassas, Elias Anaissie, Maurizio Zangari, Erik Rasmussen, Guido Tricot
Journal: Blood (2004)
AB0441 Neuropsychiatric Manifestations of Adult-Onset Systemic Lupus Erythematosus
Authors: D. Ivanova, G. Milev, S. Nacheva, I. Petrova, G. Angov, J. Petrova, K. Stoyanova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Evaluation of the diversity of Neuropsychiatric (NP) manifestations of adult-onset Systemic Lupus Erythematosus (SLE) for the period 2012–2014 (extended 2014–2015) is presented. The most common complications are migraine, cognitive and motor disorders, seizures, cerebrovascular disease <h3>Methods</h3> Complete clinical, rheumatological and neurological evaluation was performed using SLEDAI-2K, BILAG 2004, SLICC/ACR Damage Index test batteries. Immunological blood tests include C3, C4, Serum Cryoglobulins, ANA, anti-β2 GP I-Ig G, anti-β2 GP I-Ig M, Anti-double stranded DNA, anti-RNP/Sm, anti-His., Ro (SSA), La (SSB), anti-CENT B, anti-ribosomal P, ANCA followed by lumbal puncture, neuropsychological testing, Doppler sonography, EMG and EEG, brain MRI/CT. <h3>Results</h3> A total of 220 patients were longitudinally observed in 4 years period - 185 female, (84%), 35 men (16%). 82 (37%) patients presented NPSLE during the first 6 months. Consequent NP manifestations include: central vertigo (73.5%), headache (66.5%), cognitive impairment (33.2%), psychiatric disorders (18.7%), seizures (7.3%), cerebrovascular disease (10.6%), and polyneuropathy (3.5%). Positive anti-DNA antibodies (50%), anti-ribossomal P (20%), anticardiolipin antibodies (50%) were identified in NPSLE patients. <h3>Conclusions</h3> Patients with SLE present with different NP manifestations. It is still difficult to provide accurate differential diagnosis between NPSLE and chronic cerebrovascular disease or MS especially when NP manifestations are the first symptoms of SLE. <h3>Disclosure of Interest</h3> None declared
Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study
Authors: Anjali S. Advani, Holly Gundacker, Marilyn L. Slovak, Karl S. Theil, Stephen J. Forman, Jerald P. Radich, Frederick R. Appelbaum
Journal: Blood (2011)